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Abstract 
Many organic dopants have been created for use in SMOLED displays, but few are 
composed of a family of compounds that spans large portions of the visible spectrum.  
Through careful design, a small family of simple oxadiazole based tetra-coordinated 
organoboron compounds of the type B(N,O)X has been developed with emission that 
spans the visible spectrum from violet to green.  Oxadiazole based ligands were designed 
and utilized for their potential for heteroatomic substitution as well as their excellent 
electron transport properties.  Significant changes in fluorescence were observed based 
on the isomeric substitution of the naphthalene substituent.  Minimal bathochromic 
emission shifts were observed when the oxadiazole ligand was chelated with BPh2, as 
well as minimal hypsochromic shifts when chelated to BF2. This evidence suggests the 
emission of the complex is affected by the isomeric position and subsequent resonance of 
the oxadiazole ligand.  Boron clearly forms a dative bond with the lone pair from the 
nitrogen on the oxadiazole ring. The data shows that this coordination is susceptible to 
hydrolysis even with the addition of hydrophobic phenyl groups, due to the oxadiazole 
ring’s inherent electron deficiency and affinity for hydrogen bonding. This is evident 
especially in the boron trifluoride complex, in which the LCMS data shows the presence 
of only one fluoride atom.   
 
 
 
 
 iv 
 
Table of Contents 
List of Figures                              v 
List of Tables                   viii 
Chapter 1  History and Applications of Boron                               2 
  The Characteristics and Applications of Oxadiazole Compounds              4 
  Overview of LCD’s and OLED’s                               6 
  Boron and Oxadiazole compounds for OLED Applications             11 
Chapter 2 
  Synthesis and Development of New Boron Oxadiazole Complexes            16 
  Summary and Conclusions                21 
Chapter 3 
  Experimental Details                 24 
  Synthetic Methods                 24 
Bibliography                                                31 
Appendix 
UV-Vis Data                  38 
NMR Data                   41 
LC-MS Data                  62 
 
 
 v 
 
List of Figures 
FIG 1 Common chiral alpha pinene derivatives                  3 
FIG 2 Biologically active benzoboroxoles                  4 
FIG 3 Oxadiazole Isomers                   5 
FIG 4 Various luminescent oxadiazole                   6  
FIG 5 Basic LCD pixel cross-section                  7 
FIG 6 The structure of a simple OLED                            9 
FIG 7 The relative energy states of the individual layers of a basic OLED           10 
FIG 8 The Lewis acid base pairing of boron-nitride               12 
FIG 9 The core of the ubiquitous BODIPY dye and the basic scaffold of a closely related 
polydentate polypyridine dopant                 13 
FIG 10 Examples of the 2-pyridyl scaffold derivatives              14 
FIG 11 Tuning of the quinolato core                 15 
FIG 12 Excitation and emission data for HPOP               38 
FIG 13 Excitation and emission data for 1,2-HPON              38 
FIG 14 Excitation and emission data for BPh2(1,2-PON)              39 
FIG 15 Excitation and emission data for BF2(1,2-PON)              39 
FIG 16 Excitation and emission data for BPh2(2,3-PON)              40 
FIG 17 Excitation and emission data for BF2(2,3-PON)              40 
FIG 18 1HNMR Methyl 4-Methoxy-2-Naphthoate              41 
 vi 
 
FIG 19 1HNMR Methyl 4-Methoxy-2-Naphthoate              41 
FIG 20 13CNMR Methyl 4-Methoxy-2-Naphthoate               42 
FIG 21 1HNMR 4-Methoxy-2-Naphthohydrazide              42 
FIG 22 1HNMR 4-Methoxy-2-Naphthohydrazide              43 
FIG 23 13CNMR 4-Methoxy-2-Naphthohydrazide              43 
FIG 24 1HNMR N'-benzoyl-4-methoxy-2-naphthohydrazide              44 
FIG 25 1HNMR N'-benzoyl-4-methoxy-2-naphthohydrazide             45 
FIG 26 13CNMR N'-benzoyl-4-methoxy-2-naphthohydrazide             45 
FIG 27 1HNMR 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole            46 
FIG 28 13CNMR 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole           47 
FIG 29 1HNMR 1,2-HPON                  48 
FIG 30 1HNMR 1,2-HPON                  48 
FIG 31 13CNMR 1,2-HPON                  49 
FIG 32 C13NMR 1,2-HPON                   49 
FIG 33 1HNMR BF2(1,2-PON)                 50 
FIG 34 1HNMR BF2(1,2-PON)                 51 
FIG 35 13CNMR BF2(1,2-PON)                 51 
FIG 361HNMR Methyl 3-Methoxy-2-Naphthoate              52 
FIG 37 1HNMR Methyl 3-Methoxy-2-Naphthoate               52 
FIG 38 13CNMR Methyl 3-Methoxy-2-Naphthoate                53 
 vii 
 
FIG 39 1HNMR N’-Benzoyl-3-Methoxy-2-Naphthohydrazide             53 
FIG 40 1HNMR N’-Benzoyl-3-Methoxy-2-Naphthohydrazide             54 
FIG 41 13CNMR N’-Benzoyl-3-Methoxy-2-Naphthohydrazide             54 
FIG 42 1HNMR 2,3 HPON                 55 
FIG 43 1HNMR 2,3 HPON                 55 
FIG 44 13CNMR 2,3 HPON                 56 
FIG 45 13CNMR 2,3 HPON                 57 
FIG 46 1HNMR 2,3 BPH2(PON) (500 MHz, DMSO)              58 
FIG 47 1HNMR 2,3 BPH2(PON) (500 MHz, DMSO)               59 
FIG 48 1HNMR 2,3 BF2(PON) (500 MHz, DMSO)               60 
FIG 49 1HNMR 2,3 BF2(PON) (500 MHz, DMSO)               60 
FIG 50 13CNMR 2,3 BF2(PON) (500 MHz, DMSO)               61 
FIG 51 LCMS BPh2(1,2-PON)                 62 
FIG 52 LCMS BPh2(1,2-PON)                 63 
FIG 53 LCMS BF2(1,2-PON)                 64 
FIG 54 LCMS BF2(1,2-PON)                 65 
FIG 55 LCMS BPh2(2,3-PON)                 66 
FIG 56 LCMS BPh2(2,3-PON)                 67 
FIG 57 LCMS BF2(2,3-PON)                 68 
FIG 58 LCMS BF2(2,3-PON)                 69 
 viii 
 
List of Tables 
Table 1 Excitation and emission data for the oxadiazole ligands and oxadiazole complexes       23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
 
List of Schemes 
Scheme 1 Synthetic route to benzoboroxole through reduction            17 
Scheme 2 Proposed ring closing mechanism of benzoboroxole           17 
Scheme 3 Synthesis of the oxadiazole ligands             19 
Scheme 4 Chelation of the oxadiazole ligand to the boron compounds          21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
 
Abbreviations 
1,2 HPON            2-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-1-ol 
2,3 HPON                                                        3-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-2-ol 
9BBN                                                                                                                        Banana Borane   
Alq3                                                                                    Aluminum Tris(8-Hydroxyquinolato)   
BODIPY                                                                                                                  Boron Dipyrrin   
DCM                                                                                                                     Dichloromethane   
DMF                                                                                                                Dimethylformamide 
DMSO                                                                                                               Dimethyl Sulfoxide   
EDG                                                                                                        Electron Donating Group   
EML                                                                                                        Emissive Materials Layer   
ETL                                                                                                        Electron Transport Layer   
EWG                                                                                                Electron Withdrawing Group 
HOMO                                                                                 Highest Occupied Molecular Orbital 
HPOP                                                                              2-(5-phenyl-1,3,4-oxadiazol-2-yl)phenol 
HTL                                                                                                              Hole Transport Layer   
ITO                                                                                                                      Indium Tin Oxide   
LCD                                                                                                             Liquid Crystal Display   
LCMS                                                                     Liquid Chromatography Mass Spectroscopy 
LED                                                                                                                Light Emitting Diode 
LUMO                                                                              Lowest Unoccupied Molecular Orbital 
NMR                                                                          Nuclear Magnetic Resonance Spectroscopy 
 xi 
 
OLED                                                                                              Organic Light Emitting Diode   
OTf                                                                                                                                        Triflate   
PHOLED                                                                           Phosphorescent Light Emitting Diode   
PLED                                                                                           Polymeric Light Emitting Diode   
SMOLED                                                                             Small Organic Light Emitting Diode      
THF                                                                                                                       Tetrahydrofuran   
TLC                                                                                                  Thin Layer Chromatography   
UMD                                                                                             University of Minnesota-Duluth   
UV                                                                                                                                  Ultra Violet   
UV-Vis                                                                                             Ultra Violet Visible Spectrum   
 
 
 
 
 
 
 
 1 
 
Aspects and overview 
 OLED technology has progressed greatly in recent years as the demand for 
flexible displays, wider color variety, and better picture quality has increased. The 
emissive materials themselves have been the primary focus of OLED research, as such 
numerous materials have been researched and designed for that purpose.  Boron 
complexes and oxadiazoles have been used separately for organoluminescent materials, 
but little research has been done to explore a combination of their unique characteristics. 
The bulk of current luminescent organoboron compounds and oxadiazole compounds 
were investigated in this paper.  The materials researched were used in designing our own 
ligands for such emissive materials.  A new family of organoluminescent oxadiazole 
boron complexes was designed with the overall goal of color tuning of the ligand.  The 
scope of this thesis is divided into three chapters: research and design, rationalization of 
photophysical properties, and experimental.  The development process of our luminescent 
compounds with respect to what is known about organoboron compounds as well as 
oxadiazole compounds in both present and past literature is covered in the first chapter of 
this paper.  The second chapter covers the investigation into the oxadiazole based ligand, 
rationalization of luminescent properties and characterization of structural influences on 
color tuning by use of NMR, UV-Vis, and LC-MS is presented. Finally, details of 
experiments and procedures used are outlined in the third chapter. 
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Chapter 1 
The History and Application of Boron 
Boron was originally discovered in 1808 by Sir Humphry Davy, Joseph Louis Gay-
Lussac, and Louis Jacques Thenard.  Davy termed the element boracium however it was 
not officially discovered and recognized until 1828 by Jons Jako Berzelius.  It wasn’t 
until 1909 that the American chemist produced boron in its elemental form. 1,2   
Boron is fairly rare, making up only .001% of the earth’s elemental mass. The majority of 
boron containing ore deposits are found in Turkey, with the second largest deposit 
residing in the United States. 3 The most common use for boron, by mass, is the 
production of borosilicate glass from B2O3.
4,5 Boron is extracted from naturally occurring 
minerals, such as kernite and borax, and converted into boric acid.  Pure boron is derived 
from BBr3 under extreme conditions with H2, but is difficult due to impurities from 
carbon and various other trace elements.5 
 Boron is widely used in industry and scientific research. It has applications ranging from 
synthetic chemistry, medicinal uses, material science, and manufacturing.  Since the 
discovery of hydroboration, boron has been a cornerstone of organic chemistry.6 After the 
first borohydride reagent with significant synthetic applications was discovered by Brown 
and Krishnamurthy, hundreds of boron reagents have been developed. Many of the 
reagents used today were developed by Brown himself.6,7  After the naturally occurring 
alpha pinene’s properties as a chiral auxiliary for hydroboration were discovered, it has 
been used for a wide range of reactions including but not limited to reduction, 
hydroboration, homologation, enolboration, epoxide ring opening, and crotylboration all 
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of which are asymmetric and highly selective reactions FIG 1.8,9  Even the simplest of 
boron reducing agents, sodium borohydride, can be coupled with a lanthanide to perform 
highly selective reductions of alpha enones.  This is more commonly referred to as Luche 
Reduction.10 Possibly the most famous and most widely used boron reaction is the C-C 
bond forming reaction known as Suzuki Coupling. With carefully designed palladium 
catalysts, the sp2-sp2 and sp2-sp3 carbon bond forming reactions that were previously 
impossible can almost indefinitely be achieved.11  The sheer number of synthetic 
applications are too numerous and too broad in their potential applications to cover.   
 
Fig 1 Common chiral alpha pinene derivatives for use in asymetric hydroboration (1,4), 
asymmetric tosylation (2), asymmetric crotylation (3), and asymmetric homologation (5) 
The medical applications of boron are well documented with new research broadening its 
uses every day. New research into benzoboroxole derivatives has shown they exhibit 
antibiotic,12 antifungal,13 antimalarial,14 and antiprotozoal15 drugs FIG 2. Boron has been 
successfully used as an anticancer treatment in the form of B-10.16 This particular 
treatment is highly selective but has shown difficulty in the delivery of the treatment 
compounds to the affected areas in the necessary concentrations.16  
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FIG 2 Biologically active benzoboroxoles for use in antibiotics (1,2),12 antifungals 
(2),12,13 antimalarial (3),14 and antiprotozoal (4)15 drugs. 
In recent literature, boron has been incorporated and or materials designed around its 
implementation in light harvesting photovoltaics,17,18 molecular switches,19,20 lasing 
dyes,21 non-linear optics,22,23 biomolecular probes,24,25 chemosensors,26 energy transfer 
cassettes,27 and superconductors.28,29 
The majority of boron based chemosensors share many structural traits to boron based 
OLED materials,26,30-32 Generally they manipulate the same properties of boron, namely 
its empty pz orbital and natural Lewis acid character. Luminescent organoboron 
compounds are highly sensitive to the coordination and electronic environment of the 
boron, relying primarily on the conjugation of the system and the pπ-pπ* interactions 
across boron’s empty orbital.33  Three coordinate boron systems readily form dative 
bonds with strong electron donors such as fluorine, which drastically alter the overall 
luminescent properties of the compound.26,31-34 
Characteristics and Applications of Oxadiazole Compounds 
Oxadiazoles are five membered heterocyclic compounds in the azole family, with three 
stable isomers. The 1,2,4-isomer 1,3,5-isomer and 1,3,4-isomer are stable, however the 
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1,2,3-isomer undergoes ring opening forming the more stable diazoketone tautomer FIG 
3.35 
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FIG 3 The 1,2,3-oxadiazole isomer (1), 1,2,4-oxadiazole isomer (2), 1,2,4-oxadiazole 
isomer (3), and the 1,3,4-oxadiazole isomer(4). 
Oxadiazoles are inherently electron deficient overall, yet the nitrogen atoms show Lewis 
base characteristics similar to pyridine. These properties have been used with great 
success in biomedical and material science applications.   
A wide array of oxadiazole compounds have medicinal applications including 
antifungal,36 antibacterial,37-39 antimicrobial,37-43 antiviral,45 anti-HIV,46 
antitubercular,40,48 and anticancer43,45-49 pharmaceuticals with new research and 
applications occurring worldwide. The heterocyclic nature of the oxadiazole rings allow 
for high activity due to their ability to cross cell membranes efficiently allowing for 
easier uptake into targeted cells.36-49   
Oxadiazoles are excellent for material science field of optics such as nonlinear optics and 
organic light emitting diodes due to their electron deficient nature.50 NLO is a broad 
range of concepts and applications including data storage, optical communication, image 
transmission, signal processing, data storage, and optical computing while OLEDs are 
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used primarily for flat panel displays in televisions, laptops, and cellphones.55-57 
Oxadiazoles’ electron deficient nature makes them excellent electron transport 
compounds and their luminescent properties can be easily tuned by modifying the 
compounds overall electronic environment.50 This is typically done by extending the pi 
system of the compound, such as increasing the overall conjugation of the system, or by 
complexing the compound with a metal.  Various metals have been used with oxadiazole 
based compounds to great effect FIG4.50-54 
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N
O
N N
O
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FIG 4 Various luminescent oxadiazole based compounds chelated with Iridium(1)51, 
Aluminum(2)50, Biphenyl Boron(2)54, Cesium(3)52, and Tin(4)53 respectively. 
 Overview of LCD’s and OLED’s 
Since the discovery and fabrication of the first practical OLED by Tang and Van Slyke 
using the Alq3 complex,
58 a wide array of organic compounds and devices have been 
developed for their numerous advantages over modern LCD.59,60 
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The typical LCD display consists of two polarized filters and ITO electrodes that 
encapsulate the nematic liquid crystal. Incident light produced at the back of the device is 
circularly polarized by the liquid crystal, allowing it to pass through the horizontal filter. 
When a voltage is applied to the nematic crystal it straightens, there by turning off the 
pixel by keeping the light polarized vertically. The incident light is produced from a 
white backlit source while the color for each pixel is provided by an appropriately 
colored filter FIG5.61  
 
FIG 5 Basic LCD pixel cross-section.62 
This design has severely limited its efficiency and applications. The LCD operates on 
absorbing light, however as light inevitably leaches through the polarized glass the 
realization of a true black pixel reduces total emissive luminescence and global contrast 
ratio. Also the action of straightening the twisted crystals can be slow which causes 
slower refresh rates and overall blurred images.  Finally, the liquid crystal cell design 
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requires a rigid and thick structure when compared to an OLED. This prevents LCD’s 
from various applications in which OLED’s excel such as semiconducting thin films.62  
OLED devices overcome many of the short comings of LCD’s. Basic OLED’s consist of 
three simple layers; electron transport layer, emissive material layer, and hole transport 
layer.  These layers are contained between two ITO and alloy electrodes FIG 6.  These 
layers are remarkably thin compared to an LCD, no more than 10nm each, which allows 
for thinner and lighter displays.  Each of these layers are specifically designed to so that 
their semiconducting properties are compatible, in that the LUMO of the n-type ETL is 
nearly isoenergetic with the EML.  Without this compatibility the overall efficiency of 
the device is drastically reduced to the resulting charge imbalance forcing the need for 
higher voltages to operate the device.  These principles also apply to HOMO of the p-
type semiconducting layer, or the hole transport layer. This design makes each OLED 
unique in its composition and how the individual layers coordinate.  In some instances, 
based on composition and device architecture, additional layers may be required for 
optimum efficiency and functionality.  These additional layers are typically hole transport 
blockers or electron blockers located next to the EML to prevent wide band gaps.  
Materials that function as semiconductors and emissive materials are highly desirable to 
decrease the number of layers needed for device function as well as reducing the exiplex 
emission resulting from the interactions between different materials at their 
interface.59,60,63-65 
By design, OLED’s are operationally simplistic.  Charges are injected in the HTL and 
ETL FIG 7.  Physicists commonly refer to these quasiparticles as polarons. This is 
achieved by injecting electrons into the LUMO of the ETL or removing electrons from 
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the HTL. These polarons are driven by the applied voltage at the electrodes and as the 
device is operated these polarons travel, or “hop” through the layers of the OLED to the 
EML. Once they reach the EML they recombine resulting in photonic emission from the 
device by charge recombination, unlike fluorescence which is typically a result of 
electronic relaxation.59,60,63-65 The wave length of the emission corresponds to the 
fluorescence band gap of the EML used.   
 
FIG 6 The structure of a simple OLED66 
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FIG 7 The relative energy states of the individual layers of a basic OLED66.  
 Based on the broad range of semi-conducting materials available and wide variety of 
fabrication methods OLED’s can range from flexible electronic displays to solid state 
lighting.  Depending on the materials and fabrication methods used OLED’s typically fall 
into one of three categories: SMOLED, PLED, and PHOLED. From a fabrication and 
manufacturing stand point SMOLED’s are more complex to produce because they rely on 
doping via vapor deposition. However, this allows for endless synthetic possibilities for 
creating new luminescent compounds. PLED devices are highly desirable because many 
of the oligomeric chains are semi-conductive, allowing for less layers in the device.  
Additionally, these polymer chains can easily be synthesized and fabricated into flexible 
displays that are currently in high demand.  PHOLEDs are a combination of SMOLEDs 
and PLEDs, however the EML is comprised of a phosphorescent material instead of 
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fluorescent material.  Due to the spin rules of phosphorescent charge combination, 
emissions near quantum unity can be achieved.63-65  
By design, OLEDs overcome many of the limitations of LCDs.  Since the OLED operates 
based on emission instead of absorption it is over all more energy efficient by eliminating 
the need for a constant back light.  They also can achieve a true black, which is another 
major limitation in LCD devices.  Because of the switch nature of OLED design it is able 
to achieve better refresh rates. The wide array of OLED designs and composition allows 
for higher chromaticity, contrast ratios, luminosity, as well as display size and 
flexability.63-65 
OLEDs do have certain limitations.  Currently many have issues with low melting points 
which cause the pixel to short out, moisture sensitivity leading to layer degradation, and 
blue emissive materials have short lifetimes.  Yet the sheer amount of potential material 
design, architecture, and groundbreaking research insures that OLEDs will surpass 
current LCD’s in the near future.59,60,63-65 
This information is only a brief overview of OLED and LCD technology.  There is a 
massive collection of data and publications revolving around these technologies with far 
more detailed information on their complex functionality and design.59-65 
Boron and Oxadiazole Compounds for OLED Applications 
As previously discussed, OLED devices rely on the π to π orbital interactions in the 
organic semi-conductors to undergo the charge “hop” mechanism.  This necessitates the 
use of low band gap materials that are tunable for device fabrication.  Based on these 
parameters many boron based chelates have been research as alternatives to the 
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predominant transition metal based compounds.  Their chemical nature has allowed for 
the synthesis of many boron based emissive dopants that are easily tunable as EML type 
compounds.66-73 Many of boron’s unique chemical properties have fueled its application 
to OLED research.  When in the ground state boron possesses three valence electrons, 
and when in the binding state an s orbital and two p orbitals are combined into the sp2 
hybridized trigonal planer geometry, while being two electrons short of an octet.74 This 
causes boron to have a high ionization energy and covalent bond nature instead of the 
trivalent nature of other similar elements.75 Donation of electron density into boron’s 
empty p orbital can further shorten this covalent bond FIG 8.74,76 
 
FIG 8 The Lewis acid base pairing of boron-nitride adducts results in shortening of the 
bond distance (left); tetrahedral hybridization of boron (right) 
Boron’s strong Lewis acidity stems from its empty pz orbital, allowing it to readily accept 
two electrons through Lewis acid base pairing or dative bonding.5,77 A vast array of 
organic chelates exploit this property for OLED applications due to its unique ability to 
form a tetrahedral geometry when bound with a dative bond, thus locking extended π 
systems into co-planarity for maximum π system overlap. This dative bonding is usually 
with N,N or N,O chelates.  The dative bonds ability to pseudo extend the conjugated π 
system in this manner has been shown to enhance the photoluminescence of the 
 13 
 
system.78,66 Organoboron compounds are widely used as ETL for their ability to easily 
facilitate highly polarized charge transfer through boron’s pz orbital to π orbital 
interactions.67  
Boron’s covalent sigma bonding nature, due to its high charge density and small atomic 
size, provides many advantages over its group 13 counterpart, aluminum.74 Boron 
compounds are more stable than their aluminum or zinc counterparts due to this covalent 
bonding.79-82 Thus, many numerous boron based derivatives of the Alq3 compound have 
been made68-70,81,83-86, and these analogous boron compounds are what inspired our 
development of new organoboron luminescent compounds. As previously stated there are 
two main types of organoboron chelates; N,N type and N,O type.   
Simple N,N type chelates are very popular presumably due to their easy chelation with 
boron and the long term stability of the resulting compounds. Arguably the most famous 
of these chelates the BODIPY dye and its numerous derivatives FIG 9.   
                      
FIG 9 The core of the ubiquitous BODIPY dye(right)87 and the basic scaffold of a closely related 
polydentate polypyridine dopant(left)88,89
 
There are numerous publications and reviews on BODIPY and its derivatives describing 
in detail various methods of color tuning. The use of BODIPY fluorophores in OLED’s 
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however many tridentate compounds similar to the BODIPY core have been synthesized 
with OLED fabrication in mind.71-73,83,90-92 The most numerous of these are based on the 
2-pyridyl scaffold FIG 10. Small modifications to the 2-pyridyl scaffold have led to a 
wide variety of compounds with emission that span nearly all of the visible spectrum.72,73 
Further tuning of the emissions were achieved by fluorination of the scaffold, however 
the small changes in emission proved not to be cost effective based on the necessary 
materials and methods of synthesis.72 
 
FIG 10 Examples of the 2-pyridyl scaffold derivatives.72,73,91,92 
Since Tang and Van Slyke’s synthesis of the aluminum tris-quinolate scaffold N,O-type 
chelates have become the most popular and widely researched chelate with respect to 
boron based OLED applications. Many of these BArq compounds have been synthesized 
as dopants for EML, however given their versatility many have been designed into 
emissive polymers69,83 and even dual functioning multinuclear ETL-EML materials.63 
The two primary means of tuning the BArq compounds are extending the π conjugate 
system and the use of EDG or EWG substituted on the quinolate core.65,66,85,86  Research 
has shown that extending the conjugate π system or using EDG causes the emissions to 
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shift bathochromatically.70,85  The use of EWD causes the emissions to shift 
hypsochromatically70,85 FIG 11.
 
FIG 11 Tuning of the quinolato core through means of π conjugate extension (1-3)85, and 
through the use of various EDGs and EWGs on a polymeric scaffold (4)69. 
Oxadiazoles are N,O-type ligands that have been recently studied for OLED applications.  
Tang and Van Slyke extended their previous work with aluminum trisquinolate by 
replacing the quinolate with an oxadiazole, which also formed a three coordinate 
structure. Research into this new oxadiazole ligand, HPOP, showed promising results for 
OLED applications when complexed with various metals FIG 4.50 
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These luminescent boron and oxadiazole based compounds have largely been the 
influence for new OLED materials in our lab.  I have extensively researched both 
organoluminescent boron compounds as well as various oxadiazole compounds as a basis 
for designing a new family of ligands for boron based OLED materials.  Rationalization 
of color tuning techniques have been successfully implemented from the literature in 
producing new oxadiazole ligands for boron fluorophores with OLED type material 
fabrication in mind.   
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Chapter 2 
Synthesis and Development of New Boron-Oxadiazole Complexes 
Our group’s interest in organic luminescent compounds began with benzoboroxole, a 
heterocyclic polycycle that was first reported by Snyder in 1957.93 Benzoboroxole 
consists of an aromatic six membered ring and a boron containing five membered 
heterocycle.  Shortly after its discovery, it was researched for its unique synthetic 
characteristics and material applications.94-96 Benzoboroxole derivatives have been used 
for antibiotic, antifungal, antimalarial, antiprotozoal pharmaceuticals, glycoconjugates, 
Suzuki coupling, blue dyes, plastic biocides, and OLED materials.12-15,96 Recently 
colleagues in Dr. Mereddy’s lab found a simple reaction to synthesize benzoboroxole 
with consistent yields of 80 percent or more by reduction with sodium borohydride of the 
corresponding 1,2-type substituted boronic acid-aldehyde Scheme 1.  
 
 
Scheme 1 Synthetic route to benzoboroxole through reduction using sodium borohydride. 
With the improved synthesis method, many research groups at UMD sought out new uses 
for the benzoboroxole family.  It was soon discovered that benzoboroxoles, like other 
boron adducts, can be condensed with N,O-type ligands to form organoluminescent 
compounds.96  This condensation uses boron’s Lewis acidity to exploit boronic acids 
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ability to form boronic esters rapidly and reversibly with either primary or secondary 
alcohols Scheme2.97 
 
Scheme 2  Proposed mechanism of condensation in formation of boron esters. 
When benzoboroxole was condensed with 8-hydroquinolate, and more recently 10-
hydroquinolate it formed emissive compounds analogous to Tang’s Alq3.
98 Another 
compound analogous to Tang’s Alq3, Al(POP)3 showed significant results in fluorescence 
in the blue range, thus our research into combining the emissive properties of 
benzoboroxole with the tuning capabilities shown in oxadiazoles began.50 
We started by extending the π conjugate system of the oxadiazole by using the 1,2-
naphthalene and 2,3-naphthalene analog of the HPOP ligand because of its proven 
success coordinating to various metals as well as biphenyl boron.50-54 The first ligand we 
studied was the 1,2 HPON, which proved difficult to synthesize due to impurities during 
several of the steps. The addition of the hydrazide functional group proved to be the most 
difficult, with the lowest yield of pure products Scheme3. The most problematic step 
proved to be the hydrazide addition.  The original synthetic method of refluxing the 
solution yielded no product as well as no starting material. The H1NMR showed the 
formation of the carboxylic acid.  We then attempted to use the acid chloride derivative, 
however the synthesis of the acid chloride yielded many impurities and low overall 
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yields. When the hydrazide addition was attempted, the product was an insoluble dimer 
with naphthalene groups on each side. Then the original synthesis method was revisited 
under the assumption that the refluxing process caused the hydrazine to evaporate before 
the reaction could occur, despite the condenser apparatus.  When mildly heated to 70º C 
the reaction formed the desired product, however the yields were unreliable.  It 
consistently had a yield of 100% or more and the H1NMR showed a rapid hydrogen 
transfer from residual water to the primary amine. There were many attempts to remedy 
this occurrence, the used of desiccant in the condenser, molecular sieves in the solution, 
drying in vacuo,  recrystallization from various dry solvents, and even air drying. None of 
these procedures removed the residual water, and the last two procedures actually 
increased the water in the product. However, this residual water did not affect later 
reactions although the following step’s yield calculation was skewed.  Synthesis of the 
2,3-HPON was much more efficient with higher yields and minimal purification required. 
Scheme 3 Synthesis of 1,2-HPON Ligand, 2,3 HPON ligand follows the same scheme 
We then attempted to tune the emissions with EDG and EWD in the 4 position of the 
benzoboroxole’s six membered aromatic ring. Ultimately the benzoboroxoles did not 
 20 
 
chelate with either of the oxadiazole derivatives Scheme4. Many different synthesis 
methods were attempted to achieve product formation. All reactions were monitored by 
TLC. The first method was simple reflux in dry toluene. When this failed, the reaction 
temperature was increased and a Dean-Stark trap was used. However, the small amount 
of water produced by the condensation reversed the reaction to starting material too 
quickly to be removed during the reflux. Next, the reaction was attempted with molecular 
sieves in the reaction vessel as well as a Dean-Stark trap.  The slight acidity of the 
molecular sieves decomposed the oxadiazole ring and prevented the desired product 
formation.  Then we tried various hydrides to accelerate the reaction. This had the 
unintended effect of the respective hydride salt coordinating to the ligand instead of the 
boron compound. The rigid structure of the boron containing five membered heterocycle, 
reverse hydrolysis resulting in starting material, the electron repulsion of the oxygen 
heteroatom, its electron withdrawing effects, and the hydrophilic nature of the oxadiazole 
are all potential factors causing the unsuccessful chelation of the N,O-type ligand and the 
benzoboroxoles.  
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Scheme 4 Chelation of the oxadiazole ligand to the boron compounds 
Thus we moved on to other boron containing compounds. Again we used boron 
compounds with EDG and EWD to tune the emissions. The synthesis of these complexes 
were much more simplistic and efficient.  Originally the reactions were performed in 
THF at 0ºC and stirred to room temperature.  This lead to a mixture of products and a 
yield of 15% after purification.  This is presumably due to the presence of moisture in the 
THF.  Next the reactions were run in DCM under the same conditions.  Again, there were 
similar results, presumably from high humidity or condensation accumulating inside the 
flask.  Finally the reaction was run in dry DCM at room temperature and stirred.  Product 
formation occurred in approximately 30 seconds by crashing out of solution.  The 
reaction was also observed under a UV light.  This synthesis method had a yield of 80-
90% with high product purity. 
The 1,2-HPON fluoresced at 458 nm, with a 38 nm difference between excitation and 
emission peaks, while the 2,3-HPON is not fluorescent.  When bound to diphenyl boron, 
the 1,2-HPON diphenyl boron complex had strong emission at 466 nm with three 
different excitation peaks resulting in various intensities of the same emission. This 
pattern of multiple excitation peaks correlating to a single emission peak is consistent 
with previously studied oxadiazole diphenyl boron.54 In the previous case HPOP was 
complexed with diphenyl boron resulting in a similar excitation patter but an emission of 
443 nm. This shows a minute bathochromic shift of approximately 20 nm by extending 
the π system. In the case of the 1,2-HPON boron difluoride complex, again there were 
multiple excitation peaks for the emission at 436 nm, all with varying intensities of the 
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emission. Thus the effectiveness of color tuning of the 1,2-HPON ligand was minimal 
resulting in an emission shift of only 10-20 nm.   
The 2,3-HPON ligand is not fluorescent on its own. When chelated with the diphenyl 
boron it exhibited multiple excitation peaks with a single excitation peak at varying 
intensities at 506 nm. When chelated with boron difluoride, it again showed multiple 
excitation peaks of varying intensities at 492 nm. Again this shows that the electron 
environment of the boron has little effect on the emission tuning of the complex.  
Summary and Conclusions 
Our research into new luminescent oxadiazole boron complexes has shown that the major 
contributing aspect of tuning these new emissive compounds is the isomeric substitution 
of the oxadiazole ligand and its resulting resonance.  Through careful extension of the π 
system of the oxadiazole ligand we have shown this causes a minimal bathochromic shift 
of approximately 20nm on the overall fluorescence of the ligand as well as the boron 
complexes.  The original benzoboroxole oxadiazole complexes did not form. This could 
be the result of many factors.  The most likely causes are the oxadiazoles affinity for 
hydrogen bonding preventing the removal of water from the reaction before it reverses 
into the separate starting materials.  It could also be caused by the oxygen atom in the 
heterocyclic ring on the benzoboroxole removing too much electron density from the 
boron combined with the inherent electron deficiency of the oxadiazole ring.  However 
the use of more simplistic boron compounds has shown clear tetra-coordinated boron 
oxadiazole complexes with clear dative bond formation.  The use of EWD and EDG on 
the boron compound also show minimal cytochromatic and bathochromatic shifts of 
approximately 10 nm respectively.  These shifts were much smaller than anticipated.  It 
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was assumed that the combination of π system augmentation and EDG would have a 
more significant effect on the fluorescence.  The distinct change in fluorescence of the 
2,3-HPON when complexed with either boron compound shows the most efficient tuning 
method lies in the substitution and resonance of the oxadiazoles extended conjugate 
system Table1. These complexes proved to rapidly decompose in the presence of water, 
even with the use of the hydrophobic diphenyl boron complex.  This is most noticeable in 
the boron difluoride complex where the LCMS spectra shows the presence on only one 
fluoride atom due to decomposition from the minuscule amount of water in the solvent.  
The loss of two mass units indicates the formation of a BFOH oxadiazole complex with 
both the 1,2-HPON and 2,3 HPON ligands. Future research into this discovery will 
include other isomers of the HPON and further extension of the π system as well as the 
addition of more hydrophobic groups on the boron compounds to improve the 
complexes’ stability in the presence of water. 
Compound Name Excitation Wavelength (nm) Emission Wavelength (nm) 
HPOP 387 458 
BPh2(POP)(THF) 257,304,338,406 443 
1,2-HPON 396 458 
BPh2(1,2-PON) 326, 384, 425 468 
BF2(1,2-PON) 314, 341, 381, 397 436 
BPh2(2,3-PON) 326, 436 504 
BF2(2,3-PON) 343, 407 492 
Table 1 The excitation and emission data of the oxadiazole complexes 
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Chapter 3  
NMR Spectroscopy  
All spectra were taken on a Varian INOVA 500 MHz NMR spectrophotometer 
maintained at 25 degrees Celsius operating at 500 MHz for 1H NMR and 126 MHz for 
13C NMR.  The deuterated solvent used for each respective spectrum is referenced to the 
appropriate literature peak shift. Refer to the appendix for all experimental spectra.  
UV-Vis Spectroscopy 
UV-vis spectra were all taken at less than 1.0x10-5 M using a JASCO V-670 
spectrophotometer with a 1 nm band pass, using toluene as the solvent. 
LC-MS Spectroscopy 
All LC-MS spectra were taken on a Thermo Ultimate 3000 & Bruker micro OTOF-QIII 
using tetrahydrofuran as the solvent, with a concentration of 10 ppm. 
Synthesis of Benzoboroxole 
In a 500 mL round bottom flask at 0° C was added 2-formylphenylboronic acid 
(5.0183 g, 33.4709 mmol) and methanol (250 mL). Sodium borohydride (1.381 g, 
35.1445 mmol) was slowly added to the solution over a period of approximately 5 
minutes. The mixture was then stirred and removed from the ice bath allowing the flask 
to gradually warm to room temperature for a period of roughly 4 hours.  With the 
formation of various salts, the solution became cloudy.  This was then acidified by drop 
wise addition of HCl (3M, 5 mL) and extracted with ethyl acetate (3x20 mL).  The 
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organic layer was then concentrated in vacuo to yield pure benzoboroxole (3.8285 g, 
86.7% yield).  Refer to the appendix for experimental data.  
Synthesis of 6-Nitro-benzoboroxole 
In a 50 mL round bottom flask at -40° C was added 25 ml of ≥90% fuming nitric acid. 
The benzoboroxole (5.291 g, 40.01 mmol) was added over a period of 10 min while 
stirring. A thick yellow/brown slurry was formed. The slurry was stirred at -40° C for 20 
minutes. The slurry was added to 500 mL of ice water dropwise and stirred for 2 hours. A 
fine white precipitate formed. The product was recovered by vacuum filtration and 
washed (3 x 25 mL) with cold water.  The resulting powder was allowed to air dry 
overnight yielding pure 6-nitro-benzoboroxole (6.7417 g, 93% yield) 
Synthesis of 6-Amino-benzoboroxole 
In a 250 mL round bottom flask 6-nitro-benzoboroxole (5.0132 g, 28.016 mmol), 
ammonium formate (8.83 g, 63.0599 mmol), palladium catalyst (1 g , 200mg Pd/C : 1 g 
6-nitro-benzoboroxole) and anhydrous THF was stirred and allowed to reflux at 60° 
Celsius for 3 hours. The yellow solution was filtered to remove the residual 
palladium/carbon catalyst.  The filtrate was concentrated in vacuo to yield reasonably 
pure 6-amino-benzoboroxole as a fine yellow powder that was used without further 
purification (3.3866 g, 81.2% yield). 
Synthesis of 6-Dimethylamino-benzoboroxole 
In a 50 mL round bottom flask 6-amino-benzoboroxole (270 mg, 1.812 mmol), potassium 
carbonate (1.25 g, 9.064 mmol), and acetone (25 mL) was stirred while iodomethane 
(0.33 mL, 5.438 mmol) was added dropwise.  The reaction mixture was stirred for 30 
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minutes, then filtered to remover the potassium carbonate and washed with diethyl ether 
(2 x 10 mL). The filtrate was dried with magnesium sulfate, then concentrated in vacuo to 
produce pure 6-dimethylamino-benzoboroxole as an orange powder (300 mg, 93% yield). 
Synthesis of Methyl 4-methoxy-2-naphthoate 
In a 150 mL Erlenmeyer flask 1-hydroxy-2-naphthanoic acid (6.05 g, 32.15 mmol) and 
DMF (50 mL) was stirred until the solid completely dissolved. Potassium carbonate 
(16.57 g, 128.6 mmol) was added slowly to the solution as it stirred until the solution 
stopped evolving gas. Dropwise over approximately 5 minutes iodomethane (10 mL, 
160.75 mmol) was added to the solution and allowed to stir over night.  The solution was 
filtered to remove the remaining potassium carbonate, and the potassium carbonate was 
washed with DMF (3 X 10 mL).  The filtrate was then extracted with diethyl ether and 
washed with cold water (5 X 20 mL), then dried over magnesium sulfate. The filtrate was 
then concentrated in vacuo to produce a pure methyl-4-methoxy-2-naphthoate as a 
viscous brown oil (5.94 g, 85% yield).   
Synthesis of 4-methoxy-2-naphthohydrazide 
In a 100 mL round bottom flask a mixture of methyl 4-methoxy-2-naphthoate (6.227 g, 
28.796 mmol), hydrazine hydrate (6.4 mL, 55% N2H4), and ethanol (25 mL) was heated 
to 70° Celsius with a condenser overnight.  The solution was concentrated in vacuo 
yielding reasonably pure, the primary impurity being water, 4-methoxy-2-
naphthohydrazide as a brown powder that was used without further purification (7.598 g, 
yield almost quantitative, with some additional moisture in the compound).  
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Synthesis of N'-benzoyl-4-methoxy-2-naphthohydrazide 
To a mixture of 4-methoxy-2-naphthohydrazide (7.598 g, 35.139 mmol) and pyridine 
(100 mL) in a 250 mL flask cooled to 0° Celsius, was added benzoyl chloride (7.5 mL) 
dropwise over approximately 20 minutes. The solution was stirred and kept cool for 2 
hours, then allowed to stir at room temperature overnight. A creamy white precipitate 
was obtained and collected after the solution was added to 500 mL of ice/water. The 
precipitate was washed with water (3 x 25 mL), then allowed to air dry over 24 hours 
yielding pure N'-benzoyl-4-methoxy-2-naphthohydrazide as a white powder (10.022g, 
89% yield). 
Synthesis of 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
In a 250 mL round bottom flask N'-benzoyl-4-methoxy-2-naphthohydrazide (10.15 g, 
32.371 mmol) and phosphoryl chloride (100 mL) was refluxed for 24 hours.  The 
resulting yellow solution was added to 500 mL of ice/water dropwise, producing a fine 
white precipitate. The precipitate was recrystallized from ethanol producing pure 2-(1-
methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole as a fine white powder (6.74 g, 69% 
yield). 
Synthesis of 2-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-1-ol (1,2-HPON) 
In a 100 mL round bottom flask 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-
oxadiazole (4.24 g, 14.024 mmol) was dissolved in 2,4,6-lutidiene (25 mL). Then lithium 
iodide (95.63 g, 42.073 mmol) was added to the solution over a period of 2 minutes. The 
solution was heated to reflux with a condenser column packed with Dryrite. Once at 
reflux the condenser was sealed with a cap to minimize water exposure from the air.  The 
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reaction was allowed to reflux for 24 hours.  The resulting yellow solution and black 
precipitate was acidified with hydrochloric acid (2M), yielding a fine grey precipitate.  
The precipitate was recovered via filtration and washed with water (3 X 20 mL) yielding 
pure 2-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-1-ol as a grey powder (3.881 g, 96% 
yield). 
Synthesis of 2-(1-((diphenylboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
In a 100 mL round bottom flask 2-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-1-ol (228 
mg, 1 mmol) was dissolved in anhydrous THF. The solution was cooled to 0° C. Then 
triphenyl boron: THF solution (0.25M, 4 mL) was added dropwise and stirred until the 
reaction reached room temperature. After 2 hours pure 2-(1-
((diphenylboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole was precipitated as a 
pale yellow solid and filtered (0.3026 g, 66.8% yield). 
Synthesis of 2-(1-((difluoroboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
In a 100 mL round bottom flask 2-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-1-ol (200 
mg, .6936 mmol) was dissolved in DCM and cooled to 0° Celsius. Then a boron 
trifluoride: methanol solution (14%, .08 mL) was added dropwise and stirred until room 
temperature was reached.  A tan precipitate was formed and filtered off, yielding pure 2-
(1-((difluoroboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole as a fine tan 
powder (0.187 g, 75.7% yield).  
Synthesis of Methyl 3-methoxy-2-naphthoate 
In the same manner as the synthesis of Methyl 4-methoxy-2-naphthoate, the reaction of 
2-hydroxy-3-naphthanoic acid (1.00 g, 5.343 mmol) and iodomethane (0.66 mL, 26.716 
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mmol) was concentrated in vacuo yielding Methyl 3-methoxy-2-naphthoate as a viscous 
brown oil (1.129 g, 97.8% yield). Refer to the appendix for experimental data. 
Synthesis of 3-methoxy-2-naphthohydrazide 
In the same manner as the synthesis of 4-methoxy-2-naphthohydrazide, the reaction of 3-
methoxy-2-naphthohydrazide (3.86 g, 17.850 mmol) and hydrazine (4 mL, 79.92 mmol) 
was concentrated in vacuo yielding 3-methoxy-2-naphthohydrazide as a fine white 
powder (3.73 g, 96.7% yield). Refer to the appendix for experimental data. 
Synthesis of N'-benzoyl-3-methoxy-2-naphthohydrazide 
In the same manner as the synthesis of N'-benzoyl-4-methoxy-2-naphthohydrazide, the 
reaction of 3-methoxy-2-naphthohydrazide (1.681 g, 7.774 mmol) and benzoyl chloride 
(1.68 mL, 11.951 mmol) was washed with water yielding pure  N'-benzoyl-3-methoxy-2-
naphthohydrazide as a fine white powder (2.160 g, 87.2 % yield). Refer to the appendix 
for experimental data. 
Synthesis of 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
In the same manner as the synthesis of 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-
oxadiazole, the reaction of Phosphoryl chloride (1.681 g, 7.774 mmol) and Phosphoryl 
chloride (1.68 mL, 11.951 mmol) was washed with water yielding pure  2-(1-
methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole as a fine white powder (2.160 g, 
87.2 % yield). Refer to the appendix for experimental data. 
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Synthesis of Synthesis of 3-(5-phenyl-1,3,4-oxadiazol-2-yl)naphthalen-2-ol (2,3HPON) 
In the same manner as the synthesis of 1,2-HPON, 2-(1-methoxynaphthalen-2-yl)-5-
phenyl-1,3,4-oxadiazole (0.5057  g, 1.672 mmol) and Lithium  Iodide (0.6716 g, 5.018 
mmol) was reacted for 24 hours yielding 2,3-HPON (0.2142 g, .7429 mmol) as a fine 
gray powder. 
Synthesis of 3-(1-((diphenylboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
In the same manner of synthesis of 2-(1-((diphenylboranyl)oxy)naphthalen-2-yl)-5-
phenyl-1,3,4-oxadiazole, 2,3-HPON ( .2880 g, 1.0 mmol) was reacted with triphenyl 
borane (0.25M, 4 mL) was reacted at RT yielding 2-(1-
((diphenylboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole (0.3026 g, 66.8 % 
yield) as a fine yellow powder. 
Synthesis of 3-(1-((difluoroboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
In the same manner of synthesis as 2-(1-((difluoroboranyl)oxy)naphthalen-2-yl)-5-
phenyl-1,3,4-oxadiazole, 2,3-HPON (0.255 g, 0.8844 mmol) and trifluoroborane 
methanol solution (14%, 0.113 mL) was added dropwise and reacted in methanol for 2 
hours, yielding 3-(1-((difluoroboranyl)oxy)naphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole 
(0.125 g, 42.1 % yield) 
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Appendix 
All supporting experimental spectra and data are presented there within. Data is presented 
as per section of experiment; refer to the table of contents for pagination of material 
provided. 
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UV-Vis Spectroscopy and Fluorescence Spectroscopy 
 
FIG 12 Excitation and emission data for HPOP 
 
FIG 13 Excitation and emission data for 1,2-HPON 
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FIG 14 Excitation and emission data for BPh2(1,2-PON) 
 
FIG 15 Excitation and emission data for BF2(1,2-PON) 
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FIG 16 Excitation and emission data for BPh2(2,3-PON) 
 
FIG 17 Excitation and emission data for BF2(2,3-PON) 
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NMR Spectroscopy 
 
FIG 18 1HNMR Methyl 4-Methoxy-2-Naphthoate (500 MHz, CDCl3) δ 8.297, 8.279, 7.876, 
7.858, 7.844, 7.629, 7.610, 7.592, 7.577, 7.563, 4.072, 3.988 
 
FIG 19 1HNMR Methyl 4-Methoxy-2-Naphthoate (500 MHz, CDCl3) δ 8.297, 8.279, 7.876, 
7.858, 7.844, 7.629, 7.610, 7.592, 7.577, 7.563, 4.072, 3.988 
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FIG 20 13CNMR Methyl 4-Methoxy-2-Naphthoate (500 MHz, CDCl3) δ 166.693, 158.393, 
136.859, 128.651, 128.414, 127.972, 126.751, 126.629, 123.693, 119.283, 63.422, 52.27 
 
FIG 21 1HNMR 4-Methoxy-2-Naphthohydrazide (500 MHz, CDCl3) δ 9.054, 8.760, 7.913, 
7.869, 7.753, 7.737, 7.542, 7.527, 7.512, 7.418, 7.403, 7.388, 7.222, 4.231, 4.071, 4.056 
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FIG 22 1HNMR 4-Methoxy-2-Naphthohydrazide (500 MHz, CDCl3) δ 9.054, 8.760, 7.913, 
7.869, 7.753, 7.737, 7.542, 7.527, 7.512, 7.418, 7.403, 7.388, 7.222, 4.231, 4.071, 4.056 
 
FIG 23 13CNMR 4-Methoxy-2-Naphthohydrazide (500 MHz, CDCl3) δ 163.924, 161.918, 
156.235, 137.011, 132.282, 131.534, 128.735, 128.399, 128.247, 127.369, 127.316, 126.835, 
126.088, 124.844, 123.197, 119.001, 63.834 
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FIG 24 1HNMR N'-benzoyl-4-methoxy-2-naphthohydrazide (500 MHz, CDCl3) δ 8.355, 8.349, 
8.344, 8.337, 8.326, 8.222, 8.220, 8.204, 8.203, 8.168, 8.165, 8.155, 8.151, 8.149, 8.142, 7.93, 
7.788, 7.770, 7.753, 7.653, 7.651, 7.645, 7.639, 7.633, 7.627, 7.625, 7.619, 7.581, 7.578, 7.562, 
7.548, 7.286, 7.268, 7.190, 7.174, 7.170, 7.165, 4.206, 4.205, 4.204, 4.201, 4.195, 4.194, 4.188, 
4.187, 4.185, 4.161, 4.160 
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FIG 25 1HNMR N'-benzoyl-4-methoxy-2-naphthohydrazide (500 MHz, CDCl3) δ 8.355, 8.349, 
8.344, 8.337, 8.326, 8.222, 8.220, 8.204, 8.203, 8.168, 8.165, 8.155, 8.151, 8.149, 8.142, 7.93, 
7.788, 7.770, 7.753, 7.653, 7.651, 7.645, 7.639, 7.633, 7.627, 7.625, 7.619, 7.581, 7.578, 7.562, 
7.548, 7.286, 7.268, 7.190, 7.174, 7.170, 7.165, 4.206, 4.205, 4.204, 4.201, 4.195, 4.194, 4.188, 
4.187, 4.185, 4.161, 4.160 
 
FIG 26 13CNMR N'-benzoyl-4-methoxy-2-naphthohydrazide (500 MHz, CDCl3) δ 163.924, 
161.918, 156.235, 137.011, 132.282, 131.534, 128.735, 128.399, 128.247, 127.369, 127.316, 
126.835, 126.088, 124.844, 123.197, 119.001, 63.834  
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FIG 27 1HNMR 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole (500 MHz, CDCl3) δ 
8.316, 8.309, 8.304, 8.299, 8.206, 8.196, 8.144. 8.141, 8.127, 8.124, 7.905, 7.898, 7.895, 7.891, 
7.888, 7.748, 7.731, 7.616, 7.611, 7.608, 7.600, 7.597, 7.562, 7.552. 7.542, 7.529, 4.328 
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FIG 28 13CNMR 2-(1-methoxynaphthalen-2-yl)-5-phenyl-1,3,4-oxadiazole (500 MHz, CDCl3) δ 
164.687, 163.253, 156.105, 136.378, 131.710, 129.124, 129.070, 128.292, 128.147, 126.950, 
126.919, 125.218, 124.707, 124.066, 123.937, 123.258, 112.960, 63.071                                                                                                
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FIG 29 1HNMR 1,2-HPON (500 MHz, CDCl3) δ 11.142, 8.498, 8.482, 8.189, 8.177, 8.174, 
7.845, 7.831, 7.817, 7.628, 7.628, 7.614, 7.599, 7.590, 7.575, 7.560, 7.545, 7.488, 7.471 
 
FIG 30 1HNMR 1,2-HPON (500 MHz, CDCl3) δ 11.142, 8.498, 8.482, 8.189, 8.177, 8.174, 
7.845, 7.831, 7.817, 7.628, 7.628, 7.614, 7.599, 7.590, 7.575, 7.560, 7.545, 7.488, 7.471 
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FIG 31 13CNMR 1,2-HPON (500 MHz, DMSO) δ 155.51, 135.719, 132.023, 129.132, 128.781, 
127.576, 126.805, 126.104, 124.387, 123.357, 123.098, 121.557, 119.879, 101.083, 101.068. 
 
FIG 32 C13NMR 1,2-HPON  (500 MHz, DMSO) δ 155.51, 135.719, 132.023, 129.132, 128.781, 
127.576, 126.805, 126.104, 124.387, 123.357, 123.098, 121.557, 119.879, 101.083, 101.068. 
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FIG 33 1HNMR BF2(1,2-PON)(500 MHz, DMSO) δ 11.264, 8.363, 8.347, 8.189, 8.186, 8.174, 
8.170, 7.992, 7.979, 7.975, 7.964, 7.694, 7.681, 7.667, 7.663, 7.648, 7.630, 7.627, 7.616. 
 
FIG 34 1HNMR BF2(1,2-PON)(500 MHz, DMSO) δ 11.264. 8.363, 8.347, 8.189, 8.186, 8.174, 
8.170, 7.992, 7.979, 7.975, 7.964, 7.694, 7.681, 7.667, 7.663, 7.648, 7.630, 7.627, 7.616.  
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FIG 35 13CNMR BF2(1,2-PON)(500 MHz, DMSO) δ 164.817, 163.245, 154.740, 136.043, 
132.755, 129.956, 129.460, 128.377, 127.309, 126.996, 124.517, 123.479, 123.357, 123.045, 
120.611, 102.380 
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FIG 36 1HNMR Methyl 3-Methoxy-2-Naphthoate (500 MHz, CDCl3) δ8.282, 7.788, 7.771, 
7.705, 7.688, 7.495, 7.481, 7.467, 7.465, 7.355, 7.342, 7.328, 7.168, 3.956, 3.949, 3.940, 2.854, 
2.847, 2.829 
 
FIG 37 1HNMR Methyl 3-Methoxy-2-Naphthoate (500 MHz, CDCl3) δ 8.282, 7.788, 
7.771, 7.705, 7.688, 7.495, 7.481, 7.467, 7.465, 7.355, 7.342, 7.328, 7.168, 3.956, 3.949, 
3.940, 2.854, 2.847, 2.829 
 53 
 
 
FIG 38 13CNMR Methyl 3-Methoxy-2-Naphthoate (500 MHz, CDCl3) δ 166.685, 
155.678, 136.088, 132.732, 128.651, 128.399, 127.491, 126.446, 124.387, 121.702, 
106.773, 55.916, 52.224 
 
FIG 39 1HNMR N’-Benzoyl-3-Methoxy-2-Naphthohydrazide (500 MHz, CDCl3) δ 11.185, 
10.054, 8.674, 7.895, 7.821, 7.806, 7.724, 7.709, 7.494, 7.413, 7.362, 7.218, 4.130 
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FIG 40 1HNMR N’-Benzoyl-3-Methoxy-2-Naphthohydrazide (500 MHz, CDCl3) δ 11.185, 
10.054, 8.674, 7.895, 7.821, 7.806, 7.724, 7.709, 7.494, 7.413, 7.362, 7.218, 4.130 
 
FIG 41 13CNMR N’-Benzoyl-3-Methoxy-2-Naphthohydrazide (500 MHz, CDCl3) δ 160.262, 
154.450, 136.035, 133.983, 132.274, 131.511, 129.193, 128.765, 128.178, 127.308, 126.401, 
124.837, 119.543, 106.781, 56.312 
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FIG 42 1HNMR 2,3 HPON (500 MHz, DMSO) δ aromatic multiplet peaks ranging 8.46-7.36 
 
FIG 43 1HNMR 2,3 HPON (500 MHz, DMSO) δ aromatic multiplet peaks ranging 8.46-7.36 
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FIG 44 13CNMR 2,3 HPON (500 MHz, DMSO) δ 64.023, 163.825, 153.100, 136.485, 132.465, 
129.437, 128.819, 128.728, 128.613, 127.507, 127.217, 126.546, 124.502, 123.266, 111.755, 
110.733 
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FIG 45 13CNMR 2,3 HPON (500 MHz, DMSO) δ 64.023, 163.825, 153.100, 136.485, 132.465, 
129.437, 128.819, 128.728, 128.613, 127.507, 127.217, 126.546, 124.502, 123.266, 111.755, 
110.733 
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FIG 46 1HNMR 2,3 BPH2(PON) (500 MHz, DMSO) δ 9.920, 8.423, 8.288, 8.127, 8.119, 8.114, 
7.831, 7.813, 7.751, 7.736, 7.724, 7.684, 7.670, 7.684, 7.623, 7.60, 7.648, 7.623, 7.600, 7.557, 
7.530, 7.527, 7.519, 7.503, 7.442, 7.361, 7.340, 7.312, 7.300, 7.283, 7.256, 7.239, 7.227, 7.211, 
7.142, 7.127, 7.113, 7.111, 7.069, 7.057 
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FIG 47 1HNMR 2,3 BPH2(PON) (500 MHz, DMSO) δ 9.920, 8.423, 8.288, 8.127, 8.119, 8.114, 
7.831, 7.813, 7.751, 7.736, 7.724, 7.684, 7.670, 7.684, 7.623, 7.60, 7.648, 7.623, 7.600, 7.557, 
7.530, 7.527, 7.519, 7.503, 7.442, 7.361, 7.340, 7.312, 7.300, 7.283, 7.256, 7.239, 7.227, 7.211, 
7.142, 7.127, 7.113, 7.111, 7.069, 7.057 
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FIG 48 1HNMR 2,3 BF2(PON) (500 MHz, DMSO) δ 10.537, 8.767, 8.302, 8.153, 8.032, 7.958, 
7.813, 7.696, 7.589, 7.552, 3.489, 2.640, 1.643, 1.487 
 
FIG 49 1HNMR 2,3 BF2(PON) (500 MHz, DMSO) δ 10.537, 8.767, 8.302, 8.153, 8.032, 7.958, 
7.813, 7.696, 7.589, 7.552, 3.489, 2.640, 1.643, 1.487 
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FIG 50 13CNMR 2,3 BF2(PON) (500 MHz, DMSO) δ 164.275, 163.848, 153.153, 136.325, 
132.641, 130.909, 130.726, 129.971, 129.040, 128.941, 127.515, 127.210, 124.578, 123.754, 
112.876, 70.166, 47.510, 26.533 
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LCMS Spectroscopy 
FIG 51 LCMS BPh2(1,2-PON) 
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FIG 52 LCMS BPh2(1,2-PON) 
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FIG 53 LCMS BF2(1,2-PON) 
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FIG 54 LCMS BF2(1,2-PON) 
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FIG 55 LCMS BPh2(2,3-PON) 
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FIG 56 LCMS BPh2(2,3-PON) 
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FIG 
FIG 57 LCMS BF2(2,3-PON) 
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FIG 58 LCMS BF2(2,3-PON) 
